Bone density, bone quality, and FRAX: changing concepts in osteoporosis management

Chronic Excess Iodine Intake Inhibits Bone Reconstruction Leading to Osteoporosis in Rats

BACKGROUND

Although iodine modulates bone metabolism in the treatment of thyroid disease, the effect of iodine intake on bone metabolism remains less known.

OBJECTIVE

This study evaluated the effect of excess iodine intake in rats on bone reconstruction in the 6th and 12th month of intervention.

METHOD

Rats were treated with different doses of iodinated water: the normal group (NI, 6.15 μg/d), 5-fold high iodine group (5HI, 30.75 μg/d), 10-fold high iodine group (10HI, 61.5 μg/d), 50-fold high iodine group (50HI, 307.5 μg/d), and 100-fold high iodine group (100HI, 615 μg/d). Thyroid hormone concentrations were determined by a chemiluminescent immunoassay. Morphometry and microstructure of bone trabecula were observed by hematoxylin and eosin staining and microcomputed tomography, respectively. Alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRAP) staining were performed to evaluate the activity of osteoblasts and osteoclasts, respectively.

RESULTS

The 24-h urine iodine concentration increased with iodine intake. The rats in the HI groups had higher serum thyroid-stimulating hormone and decreased serum free thyroxine concentrations in the 12th month than the NI group (all P < 0.05). The percentage of the trabecular bone area and osteoblast perimeter in the 100HI group were significantly lower than those in the NI group (P < 0.05). Increased structure model index was observed in the 50HI and 100HI groups compared with the NI group in the 6th month and increased trabecular separation in the 12th month (all P < 0.05). ALP and TRAP staining revealed osteoblastic bone formation was reduced, and the number of TRAP+ multinucleated cells decreased with increasing iodine intake.

CONCLUSIONS

Excess iodine intake may increase the risk of hypothyroidism in rats. Chronic excess iodine intake can lead to abnormal changes in skeletal structure, resulting in reduced activity of osteoblasts and osteoclasts, which inhibits the process of bone reconstruction and may lead to osteoporosis.

Functional roles of fish collagen peptides on bone regeneration

Fish collagen peptides (FCP) derived from the skin, bones and scales are commercially used as a functional food or dietary supplement for hypertension and diabetes. However, there is limited evidence on the effects of FCP on the osteoblast function in contrast to evidence of the effects on wound healing, diabetes and bone regeneration, which have been obtained from animal studies. In this narrative review, we expound on the availability of FCP by basic research using osteoblasts. Low-concentration FCP upregulates the expression of osteoblast proliferation, differentiation and collagen modifying enzyme-related genes. Furthermore, it could accelerate matrix mineralization. FCP may have potential utility as a biomaterial to improve collagen quality and promote mineralization through the mitogen-activated protein kinase and Smad cascades. However, there are few clinical studies on bone regeneration in human subjects. It is desirable to be applied clinically through clinical study as soon as possible, based on the results from basic research.

A multiscale study of structural and compositional changes in a natural nanocomposite: Osteoporotic bone with chronic endogenous steroid excess

Glucocorticoid (or steroid) induced osteoporosis (GIOP) is the leading form of secondary osteoporosis, affecting up to 50% of patients receiving chronic glucocorticoid therapy. Bone quantity (bone mass) changes in GIOP patients alone are inadequate to explain the increased fracture risk, and bone material changes (bone quality) at multiple levels have been implicated in the reduced mechanics. Quantitative analysis of specific material-level changes is limited. Here, we combined multiscale experimental techniques (scanning small/wide-angle X-ray scattering/diffraction, backscattered electron imaging, and X-ray radiography) to investigate these changes in a mouse model (Crh^-120/+) with chronic endogenous steroid production. Nanoscale degree of orientation, the size distribution of mineral nanocrystals in the bone matrix, the spatial map of mineralization on the femoral cortex, and the microporosity showed significant changes between GIOP and the control, especially in the endosteal cortex. Our work can provide insight into the altered structure-property relationship leading to lowered mechanical properties in GIOP. SIGNIFICANCE STATEMENT: As a natural nanocomposite with a hierarchical structure, bone undergoes a staggered load transfer mechanism at the nanoscale. Disease and age-related deterioration of bone mechanics are caused by changes in bone structure at multiple length scales. Although clinical tools such as dual-energy X-ray absorptiometry (DXA) can be used to assess the reduction of bone quantity in these cases, little is known about how altered bone quality in diseased bone can increase fracture risk. It is clear that high-resolution diagnostic techniques need to be developed to narrow the gap between the onset and diagnosis of fracture-related changes. Here, by combining several scanning probe methods on a mouse model (Crh^-120/+) of glucocorticoid-induced osteoporosis (GIOP), we developed quantitative and spatially resolved maps of ultrastructural changes in collagen fibrils and mineral nanocrystals, mineralization distribution (microscale), and morphology (macroscale) across femoral osteoporotic bone. Our results indicate that the altered bone remodelling in GIOP leads to 1) heterogeneous bone structure and mineralization, 2) reduced degree of orientation of collagen fibrils and mineral nanocrystals, and 3) reduced length and increased thickness of mineral nanocrystals, which contribute to mechanical abnormalities. The combined multiscale experimental approach presented here will be used to understand musculoskeletal degeneration in aging and osteoporosis.

Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab

Glucocorticoid (GC)-induced osteoporosis (GIOP) is a major problem in patients with rheumatic diseases. The deleterious effect of GC on bone turnover is rapid and dose-dependent, with a predilection on the trabecular bone, resulting in vertebral fractures. Early recognition and prompt treatment of GIOP helps prevent bone loss and reduce fractures. There are pitfalls in current assessment tools for GIOP by dual-energy X-ray absorptiometry (DXA) and fracture risk assessment tool (FRAX) estimation formula. In this review, we evaluate different assessment methods for GIOP and summarize current therapies of GIOP, including the antiresorptive and anabolic agents. The potential role of newer anti-osteoporosis agent romosozumab, an anti-sclerostin monoclonal antibody, is also discussed.

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture

Introduction

Prostate cancer is a large clinical burden across Europe. It is, in fact, the most common cancer in males, accounting for more than 92,300 deaths annually throughout the continent. Prostate cancer is androgen-sensitive; thus an androgen deprivation therapy (ADT) is often used for treatment by reducing androgen to castrate levels. Several ADT agents have achieved benefits with effective palliation, but, unfortunately, severe adverse events are frequent. Contemporary ADT (Luteinising Hormone Releasing Hormone agonist - LHRHa injections) can result in side effects that include osteoporosis and fractures, compromising quality of life and survival.

Methods

In this review we analysed the associated bone toxicity consequent upon contemporary ADT and based on the literature and our own experience we present future perspectives that seek to mitigate this associated toxicity both by development of novel therapies and by better identification and prediction of fracture risk.

Results

Preliminary results indicate that parenteral oestrogen can mitigate associated osteoporotic risk and that CT scans could provide a more accurate indicator of overall bone quality and hence fracture risk.

Conclusions

As healthcare costs increase globally, cheap and effective alternatives that achieve ADT, but mitigate or avoid such bone toxicities, will be needed. More so, innovative techniques to improve both the measurement and the extent of this toxicity, by assessing bone health and prediction of fracture risk, are also required.

[Assessment of risk factors for fractures in postmenopausal women with osteoporosis]

INTRODUCTION

The main consequence of osteoporosis is bone fracture. Bone fracture risk is determined by several risk factors beyond osteodensitometric results. Some of these factors could be estimated by simple clinical questionnaires.

AIM

The aim of the present study (Score-HU) was to investigate the risk factors of bone fracture among osteoporotic postmenopausal women (n = 11,221), who were examined in an osteologic outpatient departments.

METHOD

Risk factors of each patient were recorded with the use of a simple identical data sheet.

RESULTS

The incidence of risk factors were the following: previous bone fracture (79.4%), medication (except antiporotic treatment, antihypertensive drugs 67.9%, sleeping pills 36%, antidepressants 26.5%, corticosteroids 13.5%), decreased mobility (44.6%), early menopause (31.9%), smoking (31.2%), frequent falls (29.1%), and poor health status (more than 3 chronic diseases; 24.1%).

CONCLUSIONS

Estimating the above mentioned risk factors we could assess the bone fracture risk more accurately than taking alone the bone mineral density results into consideration.